CuraTeQ Biologics Private Limited, the biologics-focused subsidiary of Aurobindo Pharma Limited, has decided to mutually terminate its licensing agreement with US-based BioFactura Inc for BFI-751, a proposed biosimilar referencing ustekinumab (Stelara). The decision follows a strategic portfolio review and forms part of CuraTeQ’s ongoing efforts to sharpen focus within its biosimilars pipeline.

Strategic Realignment of Biosimilar Portfolio

The licence agreement, signed in July 2023, was intended to support the development and commercialisation of the biosimilar across regulated global markets. As per the original terms, BioFactura was eligible to receive milestone-based payments linked to development progress and commercial achievements.

CuraTeQ retained global manufacturing rights for the product under a profit-sharing arrangement, positioning the company as a key production partner within the collaboration.

Mutual Termination With No Material Business Impact

Aurobindo Pharma confirmed that the agreement has been terminated by mutual consent, with the termination scheduled to take effect from December 27, 2025. The company emphasised that the decision is not expected to materially impact its broader biosimilars strategy or long-term growth outlook.

The move reflects CuraTeQ’s focus on resource optimisation, enabling the company to redirect investments and development efforts towards priority biologics programmes with stronger strategic alignment.

Governance and Compliance Assurance

In a regulatory clarification, Aurobindo Pharma stated that BioFactura Inc has no affiliation with the promoter or promoter group entities of the company. Consequently, the transaction does not qualify as a related-party transaction, ensuring adherence to corporate governance and disclosure requirements.

Also read: Centre Accelerates Push for TB-Free India, Stronger Drug Regulation and System-Level Transformation

As competition intensifies in the global biosimilars market, pharma companies are increasingly reassessing partnerships to ensure efficient capital allocation and pipeline relevance. CuraTeQ’s decision highlights a disciplined approach to portfolio management while reaffirming its commitment to building a sustainable and competitive biosimilars business.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!